See the DrugPatentWatch profile for yervoy

Yervoy, also known as ipilimumab, is a type of immunotherapy drug used to treat certain types of cancer. It works by stimulating the body's own immune system to fight cancer cells. According to DrugPatentWatch.com, Yervoy is approved by the US Food and Drug Administration (FDA) for the treatment of the following cancer types:

1. Melanoma: Yervoy is most commonly used for the treatment of melanoma, a type of skin cancer. It can be used for patients with advanced melanoma that has spread to other parts of the body or cannot be removed by surgery.
2. Renal cell carcinoma: Yervoy is also approved for the treatment of renal cell carcinoma, a type of kidney cancer. It is used in combination with another immunotherapy drug, nivolumab, for patients with advanced renal cell carcinoma.
3. Colorectal cancer: Yervoy is approved for the treatment of microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer. It is used in combination with nivolumab for patients with metastatic colorectal cancer that has progressed after treatment with fluoropyrimidine, oxaliplatin, and irinotecan.

It's important to note that Yervoy may not be effective for all patients with these types of cancer, and its use should be determined by a healthcare professional based on each individual patient's medical history and current health status.

Sources:

1. DrugPatentWatch.com. (n.d.). Ipilimumab. Retrieved from <https://www.drugpatentwatch.com/drugs/ipilimumab>